ME01122B - Jedinjenja i postupci za liječenje raka dojke - Google Patents

Info

Publication number

ME01122B

ME01122B MEP-2010-181A MEP18110A ME01122B ME 01122 B ME01122 B ME 01122B ME P18110 A MEP18110 A ME P18110A ME 01122 B ME01122 B ME 01122B

Authority

ME

Montenegro

Prior art keywords

cdb

progesterone

compounds

tumors

compound

Prior art date

2008-04-28

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 119
• 206010006187 Breast cancer Diseases 0.000 title claims abstract description 76
• 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 73
• 239000000044 progesterone antagonist Substances 0.000 title abstract description 9
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract description 343
• 150000001875 compounds Chemical class 0.000 claims abstract description 275
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 209
• 239000000186 progesterone Substances 0.000 claims abstract description 167
• 229960003387 progesterone Drugs 0.000 claims abstract description 166
• 238000000034 method Methods 0.000 claims abstract description 35
• 102000015694 estrogen receptors Human genes 0.000 claims abstract description 29
• 108010038795 estrogen receptors Proteins 0.000 claims abstract description 29
• 239000003862 glucocorticoid Substances 0.000 claims abstract description 20
• 102000003676 Glucocorticoid Receptors Human genes 0.000 claims abstract description 19
• 108090000079 Glucocorticoid Receptors Proteins 0.000 claims abstract description 19
• 229940011871 estrogen Drugs 0.000 claims abstract description 17
• 239000000262 estrogen Substances 0.000 claims abstract description 17
• 238000011161 development Methods 0.000 claims abstract description 14
• 210000000481 breast Anatomy 0.000 claims abstract description 13
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 13
• 210000004291 uterus Anatomy 0.000 claims abstract description 11
• 238000002657 hormone replacement therapy Methods 0.000 claims abstract description 8
• 201000011510 cancer Diseases 0.000 claims abstract description 6
• 239000000556 agonist Substances 0.000 claims abstract description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 claims abstract description 3
• JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 claims description 231
• 210000004027 cell Anatomy 0.000 claims description 126
• 230000000694 effects Effects 0.000 claims description 113
• 239000003418 antiprogestin Substances 0.000 claims description 84
• 230000000708 anti-progestin effect Effects 0.000 claims description 82
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical class C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 79
• -1 steroid esters Chemical class 0.000 claims description 71
• 102000003998 progesterone receptors Human genes 0.000 claims description 67
• 108090000468 progesterone receptors Proteins 0.000 claims description 67
• 230000035755 proliferation Effects 0.000 claims description 66
• 241001465754 Metazoa Species 0.000 claims description 63
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 56
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 46
• 239000003826 tablet Substances 0.000 claims description 46
• 210000001519 tissue Anatomy 0.000 claims description 44
• 241000700159 Rattus Species 0.000 claims description 42
• 239000011230 binding agent Substances 0.000 claims description 42
• 239000003795 chemical substances by application Substances 0.000 claims description 41
• 238000012360 testing method Methods 0.000 claims description 39
• 210000002966 serum Anatomy 0.000 claims description 35
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 32
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 32
• 108010078554 Aromatase Proteins 0.000 claims description 31
• 230000001965 increasing effect Effects 0.000 claims description 31
• 150000003839 salts Chemical class 0.000 claims description 30
• 102000014654 Aromatase Human genes 0.000 claims description 29
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 28
• 239000000872 buffer Substances 0.000 claims description 28
• 229960000890 hydrocortisone Drugs 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 28
• 235000020357 syrup Nutrition 0.000 claims description 26
• 239000006188 syrup Substances 0.000 claims description 26
• 230000006907 apoptotic process Effects 0.000 claims description 25
• 230000014509 gene expression Effects 0.000 claims description 25
• 239000003814 drug Substances 0.000 claims description 24
• 229960001603 tamoxifen Drugs 0.000 claims description 23
• 230000027455 binding Effects 0.000 claims description 22
• 239000002253 acid Substances 0.000 claims description 20
• 229960003437 aminoglutethimide Drugs 0.000 claims description 20
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 20
• 239000000843 powder Substances 0.000 claims description 20
• ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 claims description 19
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 18
• 238000000692 Student's t-test Methods 0.000 claims description 18
• 238000002474 experimental method Methods 0.000 claims description 18
• 239000000243 solution Substances 0.000 claims description 18
• 150000003431 steroids Chemical class 0.000 claims description 18
• 238000012353 t test Methods 0.000 claims description 18
• VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 claims description 17
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 claims description 17
• 230000001833 anti-estrogenic effect Effects 0.000 claims description 17
• 239000003886 aromatase inhibitor Substances 0.000 claims description 17
• 229940088597 hormone Drugs 0.000 claims description 17
• 239000005556 hormone Substances 0.000 claims description 17
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 16
• 230000004663 cell proliferation Effects 0.000 claims description 16
• 239000000796 flavoring agent Substances 0.000 claims description 16
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
• 235000019198 oils Nutrition 0.000 claims description 16
• 229940079593 drug Drugs 0.000 claims description 15
• 230000005764 inhibitory process Effects 0.000 claims description 15
• 238000002360 preparation method Methods 0.000 claims description 15
• 102000005962 receptors Human genes 0.000 claims description 15
• 108020003175 receptors Proteins 0.000 claims description 15
• 229920002472 Starch Polymers 0.000 claims description 14
• 239000003085 diluting agent Substances 0.000 claims description 14
• 230000002357 endometrial effect Effects 0.000 claims description 14
• 239000000328 estrogen antagonist Substances 0.000 claims description 14
• 235000019441 ethanol Nutrition 0.000 claims description 14
• 239000007788 liquid Substances 0.000 claims description 14
• 239000003921 oil Substances 0.000 claims description 14
• LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 14
• 230000002062 proliferating effect Effects 0.000 claims description 14
• 239000007787 solid Substances 0.000 claims description 14
• 235000019698 starch Nutrition 0.000 claims description 14
• OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
• 230000018109 developmental process Effects 0.000 claims description 13
• 230000012010 growth Effects 0.000 claims description 13
• 230000009467 reduction Effects 0.000 claims description 13
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 12
• 238000012313 Kruskal-Wallis test Methods 0.000 claims description 12
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
• 239000000853 adhesive Substances 0.000 claims description 12
• 230000001070 adhesive effect Effects 0.000 claims description 12
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
• 229960001031 glucose Drugs 0.000 claims description 12
• 229910052751 metal Inorganic materials 0.000 claims description 12
• 239000002184 metal Substances 0.000 claims description 12
• 239000000725 suspension Substances 0.000 claims description 12
• 238000007906 compression Methods 0.000 claims description 11
• 230000006835 compression Effects 0.000 claims description 11
• 231100000673 dose–response relationship Toxicity 0.000 claims description 11
• 229940122815 Aromatase inhibitor Drugs 0.000 claims description 10
• 229920002261 Corn starch Polymers 0.000 claims description 10
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
• 150000007513 acids Chemical class 0.000 claims description 10
• 238000003556 assay Methods 0.000 claims description 10
• 230000037396 body weight Effects 0.000 claims description 10
• 235000010980 cellulose Nutrition 0.000 claims description 10
• 229920002678 cellulose Polymers 0.000 claims description 10
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
• 239000000839 emulsion Substances 0.000 claims description 10
• 239000000194 fatty acid Substances 0.000 claims description 10
• 229930195729 fatty acid Natural products 0.000 claims description 10
• 239000004615 ingredient Substances 0.000 claims description 10
• 239000002502 liposome Substances 0.000 claims description 10
• 239000011777 magnesium Substances 0.000 claims description 10
• 229910052749 magnesium Inorganic materials 0.000 claims description 10
• 229940091250 magnesium supplement Drugs 0.000 claims description 10
• 238000002156 mixing Methods 0.000 claims description 10
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
• 239000003755 preservative agent Substances 0.000 claims description 10
• 239000000583 progesterone congener Substances 0.000 claims description 10
• 239000000126 substance Substances 0.000 claims description 10
• 150000001412 amines Chemical class 0.000 claims description 9
• 229940046836 anti-estrogen Drugs 0.000 claims description 9
• 230000001076 estrogenic effect Effects 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 229940124597 therapeutic agent Drugs 0.000 claims description 9
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 8
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
• 229920000858 Cyclodextrin Polymers 0.000 claims description 8
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 8
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
• 238000000540 analysis of variance Methods 0.000 claims description 8
• 230000000181 anti-adherent effect Effects 0.000 claims description 8
• 239000002585 base Substances 0.000 claims description 8
• 230000004071 biological effect Effects 0.000 claims description 8
• 210000004369 blood Anatomy 0.000 claims description 8
• 239000008280 blood Substances 0.000 claims description 8
• 239000002775 capsule Substances 0.000 claims description 8
• 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
• 239000008120 corn starch Substances 0.000 claims description 8
• 239000007884 disintegrant Substances 0.000 claims description 8
• 239000002552 dosage form Substances 0.000 claims description 8
• 229960003399 estrone Drugs 0.000 claims description 8
• 235000019634 flavors Nutrition 0.000 claims description 8
• 235000013355 food flavoring agent Nutrition 0.000 claims description 8
• 235000003599 food sweetener Nutrition 0.000 claims description 8
• 239000008187 granular material Substances 0.000 claims description 8
• 238000002347 injection Methods 0.000 claims description 8
• 239000007924 injection Substances 0.000 claims description 8
• 239000008101 lactose Substances 0.000 claims description 8
• 229960001375 lactose Drugs 0.000 claims description 8
• 239000000314 lubricant Substances 0.000 claims description 8
• 235000019359 magnesium stearate Nutrition 0.000 claims description 8
• 239000002609 medium Substances 0.000 claims description 8
• 229920000609 methyl cellulose Polymers 0.000 claims description 8
• 235000010981 methylcellulose Nutrition 0.000 claims description 8
• 239000001923 methylcellulose Substances 0.000 claims description 8
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
• 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
• 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
• 230000007935 neutral effect Effects 0.000 claims description 8
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
• 239000008159 sesame oil Substances 0.000 claims description 8
• 235000011803 sesame oil Nutrition 0.000 claims description 8
• 238000003860 storage Methods 0.000 claims description 8
• 238000010254 subcutaneous injection Methods 0.000 claims description 8
• 239000007929 subcutaneous injection Substances 0.000 claims description 8
• 239000003765 sweetening agent Substances 0.000 claims description 8
• 239000000454 talc Substances 0.000 claims description 8
• 229910052623 talc Inorganic materials 0.000 claims description 8
• 229940033134 talc Drugs 0.000 claims description 8
• 235000012222 talc Nutrition 0.000 claims description 8
• 229960003604 testosterone Drugs 0.000 claims description 8
• 239000000080 wetting agent Substances 0.000 claims description 8
• 108010078791 Carrier Proteins Proteins 0.000 claims description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
• 102000040945 Transcription factor Human genes 0.000 claims description 7
• 108091023040 Transcription factor Proteins 0.000 claims description 7
• 230000002280 anti-androgenic effect Effects 0.000 claims description 7
• 229940046844 aromatase inhibitors Drugs 0.000 claims description 7
• 230000003247 decreasing effect Effects 0.000 claims description 7
• 230000001419 dependent effect Effects 0.000 claims description 7
• 238000000227 grinding Methods 0.000 claims description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
• 230000035407 negative regulation of cell proliferation Effects 0.000 claims description 7
• ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 7
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 6
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
• 238000002965 ELISA Methods 0.000 claims description 6
• 240000002943 Elettaria cardamomum Species 0.000 claims description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
• 238000000729 Fisher's exact test Methods 0.000 claims description 6
• 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 6
• 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
• 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
• 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 6
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
• 240000007472 Leucaena leucocephala Species 0.000 claims description 6
• 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 6
• 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
• 244000246386 Mentha pulegium Species 0.000 claims description 6
• 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
• 229930006000 Sucrose Natural products 0.000 claims description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 6
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 6
• 235000009499 Vanilla fragrans Nutrition 0.000 claims description 6
• 244000263375 Vanilla tahitensis Species 0.000 claims description 6
• 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 6
• 238000002835 absorbance Methods 0.000 claims description 6
• 208000009956 adenocarcinoma Diseases 0.000 claims description 6
• 235000010443 alginic acid Nutrition 0.000 claims description 6
• 229920000615 alginic acid Polymers 0.000 claims description 6
• 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
• 238000004458 analytical method Methods 0.000 claims description 6
• 239000002518 antifoaming agent Substances 0.000 claims description 6
• 239000003963 antioxidant agent Substances 0.000 claims description 6
• 238000011888 autopsy Methods 0.000 claims description 6
• 230000008901 benefit Effects 0.000 claims description 6
• 239000011575 calcium Substances 0.000 claims description 6
• 229960005069 calcium Drugs 0.000 claims description 6
• 229910052791 calcium Inorganic materials 0.000 claims description 6
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
• 235000005300 cardamomo Nutrition 0.000 claims description 6
• 239000001913 cellulose Substances 0.000 claims description 6
• 239000007891 compressed tablet Substances 0.000 claims description 6
• 210000000172 cytosol Anatomy 0.000 claims description 6
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
• 229960003957 dexamethasone Drugs 0.000 claims description 6
• 239000008121 dextrose Substances 0.000 claims description 6
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
• 239000003623 enhancer Substances 0.000 claims description 6
• 229960005309 estradiol Drugs 0.000 claims description 6
• 229930182833 estradiol Natural products 0.000 claims description 6
• 239000012458 free base Substances 0.000 claims description 6
• 239000000499 gel Substances 0.000 claims description 6
• 239000008103 glucose Substances 0.000 claims description 6
• 238000005469 granulation Methods 0.000 claims description 6
• 230000003179 granulation Effects 0.000 claims description 6
• 235000001050 hortel pimenta Nutrition 0.000 claims description 6
• 239000001257 hydrogen Chemical group 0.000 claims description 6
• 229910052739 hydrogen Inorganic materials 0.000 claims description 6
• 238000003364 immunohistochemistry Methods 0.000 claims description 6
• 229940010454 licorice Drugs 0.000 claims description 6
• 229940069445 licorice extract Drugs 0.000 claims description 6
• 238000005259 measurement Methods 0.000 claims description 6
• 150000002739 metals Chemical class 0.000 claims description 6
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 6
• 238000007911 parenteral administration Methods 0.000 claims description 6
• 229940069328 povidone Drugs 0.000 claims description 6
• 230000008569 process Effects 0.000 claims description 6
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
• 229910052708 sodium Inorganic materials 0.000 claims description 6
• 229940083542 sodium Drugs 0.000 claims description 6
• 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
• 239000001488 sodium phosphate Substances 0.000 claims description 6
• 239000007909 solid dosage form Substances 0.000 claims description 6
• 235000010356 sorbitol Nutrition 0.000 claims description 6
• 239000000600 sorbitol Substances 0.000 claims description 6
• 239000003270 steroid hormone Substances 0.000 claims description 6
• 238000007920 subcutaneous administration Methods 0.000 claims description 6
• 239000005720 sucrose Substances 0.000 claims description 6
• 229940098465 tincture Drugs 0.000 claims description 6
• 230000003442 weekly effect Effects 0.000 claims description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
• 241000282412 Homo Species 0.000 claims description 5
• 125000003342 alkenyl group Chemical group 0.000 claims description 5
• 125000000304 alkynyl group Chemical group 0.000 claims description 5
• 239000004359 castor oil Substances 0.000 claims description 5
• 235000019438 castor oil Nutrition 0.000 claims description 5
• 230000030833 cell death Effects 0.000 claims description 5
• 238000009472 formulation Methods 0.000 claims description 5
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 230000003993 interaction Effects 0.000 claims description 5
• 230000003068 static effect Effects 0.000 claims description 5
• 230000002195 synergetic effect Effects 0.000 claims description 5
• 230000002103 transcriptional effect Effects 0.000 claims description 5
• 210000004881 tumor cell Anatomy 0.000 claims description 5
• 230000004614 tumor growth Effects 0.000 claims description 5
• JFEPJTGMGDGPHJ-PNKHAZJDSA-N (8r,9s,10r,13s,14s)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 JFEPJTGMGDGPHJ-PNKHAZJDSA-N 0.000 claims description 4
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 4
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
• 235000007173 Abies balsamea Nutrition 0.000 claims description 4
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 4
• 239000004857 Balsam Substances 0.000 claims description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
• QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
• 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
• 235000005747 Carum carvi Nutrition 0.000 claims description 4
• 240000000467 Carum carvi Species 0.000 claims description 4
• 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
• 239000001856 Ethyl cellulose Substances 0.000 claims description 4
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
• 108010010803 Gelatin Proteins 0.000 claims description 4
• 244000018716 Impatiens biflora Species 0.000 claims description 4
• 229930195725 Mannitol Natural products 0.000 claims description 4
• 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
• 235000014749 Mentha crispa Nutrition 0.000 claims description 4
• 244000024873 Mentha crispa Species 0.000 claims description 4
• 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
• 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
• 229910019142 PO4 Inorganic materials 0.000 claims description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
• 235000009470 Theobroma cacao Nutrition 0.000 claims description 4
• 244000299461 Theobroma cacao Species 0.000 claims description 4
• 229920001615 Tragacanth Polymers 0.000 claims description 4
• 150000001242 acetic acid derivatives Chemical class 0.000 claims description 4
• 239000000443 aerosol Substances 0.000 claims description 4
• 239000000783 alginic acid Substances 0.000 claims description 4
• 229960001126 alginic acid Drugs 0.000 claims description 4
• 150000001342 alkaline earth metals Chemical class 0.000 claims description 4
• 229910052782 aluminium Inorganic materials 0.000 claims description 4
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
• 229960002932 anastrozole Drugs 0.000 claims description 4
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 4
• 230000001548 androgenic effect Effects 0.000 claims description 4
• 230000001028 anti-proliverative effect Effects 0.000 claims description 4
• 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
• 125000003118 aryl group Chemical group 0.000 claims description 4
• 239000000440 bentonite Substances 0.000 claims description 4
• 229910000278 bentonite Inorganic materials 0.000 claims description 4
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
• 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
• 150000001642 boronic acid derivatives Chemical class 0.000 claims description 4
• 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
• 229960003563 calcium carbonate Drugs 0.000 claims description 4
• 235000010216 calcium carbonate Nutrition 0.000 claims description 4
• 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
• 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
• 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
• 238000012754 cardiac puncture Methods 0.000 claims description 4
• 239000000969 carrier Substances 0.000 claims description 4
• 238000006243 chemical reaction Methods 0.000 claims description 4
• 235000017803 cinnamon Nutrition 0.000 claims description 4
• 150000001860 citric acid derivatives Chemical class 0.000 claims description 4
• 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
• 239000006071 cream Substances 0.000 claims description 4
• 239000013078 crystal Substances 0.000 claims description 4
• 229940097362 cyclodextrins Drugs 0.000 claims description 4
• FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 claims description 4
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
• 238000007908 dry granulation Methods 0.000 claims description 4
• 239000003995 emulsifying agent Substances 0.000 claims description 4
• 230000002708 enhancing effect Effects 0.000 claims description 4
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 4
• 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
• 229920001249 ethyl cellulose Polymers 0.000 claims description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
• 229960000255 exemestane Drugs 0.000 claims description 4
• 239000000284 extract Substances 0.000 claims description 4
• 239000003925 fat Substances 0.000 claims description 4
• 235000019197 fats Nutrition 0.000 claims description 4
• 150000004665 fatty acids Chemical class 0.000 claims description 4
• 239000012091 fetal bovine serum Substances 0.000 claims description 4
• 239000008273 gelatin Substances 0.000 claims description 4
• 229920000159 gelatin Polymers 0.000 claims description 4
• 235000019322 gelatine Nutrition 0.000 claims description 4
• 235000011852 gelatine desserts Nutrition 0.000 claims description 4
• 210000004907 gland Anatomy 0.000 claims description 4
• 125000005456 glyceride group Chemical group 0.000 claims description 4
• 235000011187 glycerol Nutrition 0.000 claims description 4
• 150000004677 hydrates Chemical class 0.000 claims description 4
• 238000011534 incubation Methods 0.000 claims description 4
• 230000006698 induction Effects 0.000 claims description 4
• 238000001361 intraarterial administration Methods 0.000 claims description 4
• 238000007918 intramuscular administration Methods 0.000 claims description 4
• 238000007912 intraperitoneal administration Methods 0.000 claims description 4
• 238000007913 intrathecal administration Methods 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 150000002611 lead compounds Chemical class 0.000 claims description 4
• 229960003881 letrozole Drugs 0.000 claims description 4
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
• 238000005461 lubrication Methods 0.000 claims description 4
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
• 239000000347 magnesium hydroxide Substances 0.000 claims description 4
• 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
• 235000012254 magnesium hydroxide Nutrition 0.000 claims description 4
• 239000000391 magnesium silicate Substances 0.000 claims description 4
• 239000000594 mannitol Substances 0.000 claims description 4
• 235000010355 mannitol Nutrition 0.000 claims description 4
• 230000000873 masking effect Effects 0.000 claims description 4
• 239000001220 mentha spicata Substances 0.000 claims description 4
• 108020004999 messenger RNA Proteins 0.000 claims description 4
• 229960001207 micronized progesterone Drugs 0.000 claims description 4
• 235000015097 nutrients Nutrition 0.000 claims description 4
• 239000002674 ointment Substances 0.000 claims description 4
• 150000002923 oximes Chemical class 0.000 claims description 4
• QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
• 238000007427 paired t-test Methods 0.000 claims description 4
• 201000010198 papillary carcinoma Diseases 0.000 claims description 4
• 239000002245 particle Substances 0.000 claims description 4
• 230000035515 penetration Effects 0.000 claims description 4
• 235000021317 phosphate Nutrition 0.000 claims description 4
• 229920001223 polyethylene glycol Polymers 0.000 claims description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
• OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 claims description 4
• 235000011009 potassium phosphates Nutrition 0.000 claims description 4
• 229920003124 powdered cellulose Polymers 0.000 claims description 4
• 235000019814 powdered cellulose Nutrition 0.000 claims description 4
• 230000003623 progesteronic effect Effects 0.000 claims description 4
• 125000006239 protecting group Chemical group 0.000 claims description 4
• 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
• 238000002271 resection Methods 0.000 claims description 4
• 238000003757 reverse transcription PCR Methods 0.000 claims description 4
• 239000011734 sodium Substances 0.000 claims description 4
• 239000001632 sodium acetate Substances 0.000 claims description 4
• 235000017281 sodium acetate Nutrition 0.000 claims description 4
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 4
• 235000011008 sodium phosphates Nutrition 0.000 claims description 4
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 4
• 239000002904 solvent Substances 0.000 claims description 4
• 235000011069 sorbitan monooleate Nutrition 0.000 claims description 4
• 239000001593 sorbitan monooleate Substances 0.000 claims description 4
• 229940035049 sorbitan monooleate Drugs 0.000 claims description 4
• 229940032147 starch Drugs 0.000 claims description 4
• 239000008107 starch Substances 0.000 claims description 4
• 239000004094 surface-active agent Substances 0.000 claims description 4
• 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 4
• 230000001225 therapeutic effect Effects 0.000 claims description 4
• RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 4
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
• 230000005751 tumor progression Effects 0.000 claims description 4
• 235000012141 vanillin Nutrition 0.000 claims description 4
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 4
• 238000001262 western blot Methods 0.000 claims description 4
• 238000005550 wet granulation Methods 0.000 claims description 4
• RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 claims description 3
• 108010029485 Protein Isoforms Proteins 0.000 claims description 3
• 102000001708 Protein Isoforms Human genes 0.000 claims description 3
• QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
• 125000004423 acyloxy group Chemical group 0.000 claims description 3
• 125000000217 alkyl group Chemical group 0.000 claims description 3
• GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 claims description 3
• 239000003183 carcinogenic agent Substances 0.000 claims description 3
• 125000005265 dialkylamine group Chemical group 0.000 claims description 3
• 230000007773 growth pattern Effects 0.000 claims description 3
• 229910052736 halogen Inorganic materials 0.000 claims description 3
• 125000001475 halogen functional group Chemical group 0.000 claims description 3
• 150000002367 halogens Chemical class 0.000 claims description 3
• 150000002431 hydrogen Chemical group 0.000 claims description 3
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
• 238000007689 inspection Methods 0.000 claims description 3
• 230000003902 lesion Effects 0.000 claims description 3
• 210000005075 mammary gland Anatomy 0.000 claims description 3
• CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 claims description 3
• 238000003801 milling Methods 0.000 claims description 3
• 230000002018 overexpression Effects 0.000 claims description 3
• 230000004044 response Effects 0.000 claims description 3
• 230000001629 suppression Effects 0.000 claims description 3
• 238000001356 surgical procedure Methods 0.000 claims description 3
• 238000013518 transcription Methods 0.000 claims description 3
• 230000035897 transcription Effects 0.000 claims description 3
• FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
• SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 claims description 2
• IIURABUWDUCHOI-UHFFFAOYSA-N (3,4-dichlorophenyl)-(6-phenyl-4,5-dihydro-3h-pyridazin-2-yl)methanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1N=C(C=2C=CC=CC=2)CCC1 IIURABUWDUCHOI-UHFFFAOYSA-N 0.000 claims description 2
• OJAOAAIVTHLNSZ-UAGQMJEPSA-N (3ar,3bs,11as)-11a-methyl-3,3a,3b,5,8,9,10,11-octahydro-2h-indeno[4,5-c]isochromene-1,7-dione Chemical compound C1CC(=O)C=C2CO[C@@H]([C@H]3[C@@](C)(C(CC3)=O)CC3)C3=C21 OJAOAAIVTHLNSZ-UAGQMJEPSA-N 0.000 claims description 2
• HFDGABTZPISMDD-IEVXGSBISA-N (6r,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-6,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C([C@H]1[C@@H]2C[C@H](C3=CC(=O)CCC3=C2[C@H](C[C@@]11C)C=2C=CC(=CC=2)N(C)C)C)C[C@]21CCCO2 HFDGABTZPISMDD-IEVXGSBISA-N 0.000 claims description 2
• WFPOBMHQGIPWFB-GCLUAJDJSA-N (7s,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-7,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C([C@@H]1[C@]2(C)C[C@@H](C3=C4CCC(=O)C=C4C[C@@H]([C@@H]13)C)C=1C=CC(=CC=1)N(C)C)C[C@@]21CCCO1 WFPOBMHQGIPWFB-GCLUAJDJSA-N 0.000 claims description 2
• DJNCIZXYDJFEDV-SQNIBIBYSA-N (8S,13S,14S)-13-(2,2,3,3,3-pentafluoropropyl)-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(CC(F)(F)C(F)(F)F)CC2 DJNCIZXYDJFEDV-SQNIBIBYSA-N 0.000 claims description 2
• IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 claims description 2
• YNWTZVKFWBTFFE-ONBAZCQBSA-N (8s,11r,13s,14s,17r)-11-(4-acetylphenyl)-13-methyl-3'-methylidenespiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C1=CC(C(=O)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]23C(CCO3)=C)[C@]2(C)C1 YNWTZVKFWBTFFE-ONBAZCQBSA-N 0.000 claims description 2
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 claims description 2
• OJWMDOIYUCEXNF-UHFFFAOYSA-N 1,3-dihydro-2,1-benzothiazole 2,2-dioxide Chemical class C1=CC=C2NS(=O)(=O)CC2=C1 OJWMDOIYUCEXNF-UHFFFAOYSA-N 0.000 claims description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
• AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims description 2
• AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 2
• ANVNKIIPNMMMAE-UHFFFAOYSA-N 2,3-dihydro-1h-chromeno[3,4-f]quinoline Chemical class C1=CC=C2OC=C3C4=CCCNC4=CC=C3C2=C1 ANVNKIIPNMMMAE-UHFFFAOYSA-N 0.000 claims description 2
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
• CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 2
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
• ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims description 2
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
• 150000000655 7-oxasteroids Chemical class 0.000 claims description 2
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
• 229920001817 Agar Polymers 0.000 claims description 2
• 235000019489 Almond oil Nutrition 0.000 claims description 2
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
• 244000144725 Amygdalus communis Species 0.000 claims description 2
• 235000011437 Amygdalus communis Nutrition 0.000 claims description 2
• 229920000856 Amylose Polymers 0.000 claims description 2
• 241000416162 Astragalus gummifer Species 0.000 claims description 2
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
• 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
• 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
• 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
• 240000008886 Ceratonia siliqua Species 0.000 claims description 2
• 235000005979 Citrus limon Nutrition 0.000 claims description 2
• 244000131522 Citrus pyriformis Species 0.000 claims description 2
• 235000005976 Citrus sinensis Nutrition 0.000 claims description 2
• 240000002319 Citrus sinensis Species 0.000 claims description 2
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 2
• 235000007129 Cuminum cyminum Nutrition 0.000 claims description 2
• 244000304337 Cuminum cyminum Species 0.000 claims description 2
• 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 2
• 108020004414 DNA Proteins 0.000 claims description 2
• 229920002307 Dextran Polymers 0.000 claims description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
• 238000012286 ELISA Assay Methods 0.000 claims description 2
• 238000008157 ELISA kit Methods 0.000 claims description 2
• 102000004190 Enzymes Human genes 0.000 claims description 2
• 108090000790 Enzymes Proteins 0.000 claims description 2
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
• 208000007659 Fibroadenoma Diseases 0.000 claims description 2
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 2
• 229920002907 Guar gum Polymers 0.000 claims description 2
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
• 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
• 235000019501 Lemon oil Nutrition 0.000 claims description 2
• 108060001084 Luciferase Proteins 0.000 claims description 2
• 239000005089 Luciferase Substances 0.000 claims description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
• 239000004472 Lysine Substances 0.000 claims description 2
• 239000005913 Maltodextrin Substances 0.000 claims description 2
• 229920002774 Maltodextrin Polymers 0.000 claims description 2
• 241000124008 Mammalia Species 0.000 claims description 2
• 238000000585 Mann–Whitney U test Methods 0.000 claims description 2
• 229920000881 Modified starch Polymers 0.000 claims description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
• 206010061309 Neoplasm progression Diseases 0.000 claims description 2
• 235000019502 Orange oil Nutrition 0.000 claims description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
• 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
• 241000288906 Primates Species 0.000 claims description 2
• 235000010401 Prunus avium Nutrition 0.000 claims description 2
• 241001290151 Prunus avium subsp. avium Species 0.000 claims description 2
• 240000008296 Prunus serotina Species 0.000 claims description 2
• 235000014441 Prunus serotina Nutrition 0.000 claims description 2
• 108091027981 Response element Proteins 0.000 claims description 2
• 235000008981 Smilax officinalis Nutrition 0.000 claims description 2
• 240000002493 Smilax officinalis Species 0.000 claims description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
• 239000001744 Sodium fumarate Substances 0.000 claims description 2
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 2
• IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
• 235000021355 Stearic acid Nutrition 0.000 claims description 2
• 108010085012 Steroid Receptors Proteins 0.000 claims description 2
• 239000004376 Sucralose Substances 0.000 claims description 2
• 239000007983 Tris buffer Substances 0.000 claims description 2
• HKDLNTKNLJPAIY-WKWWZUSTSA-N Ulipristal Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 claims description 2
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
• 244000273928 Zingiber officinale Species 0.000 claims description 2
• 235000006886 Zingiber officinale Nutrition 0.000 claims description 2
• MCABXKINPWWXRD-GJDJGZIVSA-N [(8s,11r,13s,14s,17r)-17-(2-methoxyacetyl)-13-methyl-11-[4-(methylamino)phenyl]-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC(NC)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(=O)COC)[C@]2(C)C1 MCABXKINPWWXRD-GJDJGZIVSA-N 0.000 claims description 2
• AFUBKIQQSUBSGF-LNAXGRFASA-N [(8s,11r,13s,14s,17r)-17-acetyl-13-methyl-3-oxo-11-(4-piperidin-1-ylphenyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(OC(=O)C)C(C)=O)=CC=C1N1CCCCC1 AFUBKIQQSUBSGF-LNAXGRFASA-N 0.000 claims description 2
• YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 2
• 230000003187 abdominal effect Effects 0.000 claims description 2
• 239000000654 additive Substances 0.000 claims description 2
• 201000004471 adenofibroma Diseases 0.000 claims description 2
• 239000008272 agar Substances 0.000 claims description 2
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 2
• 150000004781 alginic acids Chemical class 0.000 claims description 2
• 125000002723 alicyclic group Chemical group 0.000 claims description 2
• 125000001931 aliphatic group Chemical group 0.000 claims description 2
• 239000003513 alkali Substances 0.000 claims description 2
• 150000005215 alkyl ethers Chemical class 0.000 claims description 2
• 235000020224 almond Nutrition 0.000 claims description 2
• 239000008168 almond oil Substances 0.000 claims description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
• 229940063655 aluminum stearate Drugs 0.000 claims description 2
• UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 claims description 2
• 150000001413 amino acids Chemical class 0.000 claims description 2
• AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 2
• 229960005471 androstenedione Drugs 0.000 claims description 2
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 2
• 229940011037 anethole Drugs 0.000 claims description 2
• 239000010617 anise oil Substances 0.000 claims description 2
• 230000003042 antagnostic effect Effects 0.000 claims description 2
• 230000002800 anti-glucocorticoid effect Effects 0.000 claims description 2
• 230000002513 anti-ovulatory effect Effects 0.000 claims description 2
• 229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 2
• 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims description 2
• 238000003782 apoptosis assay Methods 0.000 claims description 2
• 239000008365 aqueous carrier Substances 0.000 claims description 2
• 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
• 229960003872 benzethonium Drugs 0.000 claims description 2
• 229960001950 benzethonium chloride Drugs 0.000 claims description 2
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
• 150000008641 benzimidazolones Chemical class 0.000 claims description 2
• 150000005130 benzoxazines Chemical class 0.000 claims description 2
• 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
• 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
• 238000004166 bioassay Methods 0.000 claims description 2
• 230000015572 biosynthetic process Effects 0.000 claims description 2
• 229920001400 block copolymer Polymers 0.000 claims description 2
• 229910021538 borax Inorganic materials 0.000 claims description 2
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
• 239000004327 boric acid Substances 0.000 claims description 2
• 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
• 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
• 229940067596 butylparaben Drugs 0.000 claims description 2
• VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
• 235000011092 calcium acetate Nutrition 0.000 claims description 2
• 239000001639 calcium acetate Substances 0.000 claims description 2
• 229960005147 calcium acetate Drugs 0.000 claims description 2
• NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
• 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 2
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
• 239000001354 calcium citrate Substances 0.000 claims description 2
• 229960004256 calcium citrate Drugs 0.000 claims description 2
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
• 239000004227 calcium gluconate Substances 0.000 claims description 2
• 235000013927 calcium gluconate Nutrition 0.000 claims description 2
• 229960004494 calcium gluconate Drugs 0.000 claims description 2
• 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
• UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
• 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 2
• 239000000920 calcium hydroxide Substances 0.000 claims description 2
• 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
• 229940095643 calcium hydroxide Drugs 0.000 claims description 2
• 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
• 239000001527 calcium lactate Substances 0.000 claims description 2
• 235000011086 calcium lactate Nutrition 0.000 claims description 2
• 229960002401 calcium lactate Drugs 0.000 claims description 2
• 239000001506 calcium phosphate Substances 0.000 claims description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
• 235000011010 calcium phosphates Nutrition 0.000 claims description 2
• GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 claims description 2
• 235000011035 calcium tartrate Nutrition 0.000 claims description 2
• 239000001427 calcium tartrate Substances 0.000 claims description 2
• MQRKKLAGBPVXCD-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one;hydrate Chemical compound O.[Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 MQRKKLAGBPVXCD-UHFFFAOYSA-L 0.000 claims description 2
• NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
• UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 claims description 2
• PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 2
• PYSZASIZWHHPHJ-UHFFFAOYSA-L calcium;phthalate Chemical compound [Ca+2].[O-]C(=O)C1=CC=CC=C1C([O-])=O PYSZASIZWHHPHJ-UHFFFAOYSA-L 0.000 claims description 2
• 230000009702 cancer cell proliferation Effects 0.000 claims description 2
• 230000000711 cancerogenic effect Effects 0.000 claims description 2
• 150000005323 carbonate salts Chemical class 0.000 claims description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
• 150000001735 carboxylic acids Chemical class 0.000 claims description 2
• 231100000357 carcinogen Toxicity 0.000 claims description 2
• 235000010418 carrageenan Nutrition 0.000 claims description 2
• 239000000679 carrageenan Substances 0.000 claims description 2
• 229920001525 carrageenan Polymers 0.000 claims description 2
• 229940113118 carrageenan Drugs 0.000 claims description 2
• 150000001768 cations Chemical class 0.000 claims description 2
• 210000000170 cell membrane Anatomy 0.000 claims description 2
• 239000013553 cell monolayer Substances 0.000 claims description 2
• 238000001516 cell proliferation assay Methods 0.000 claims description 2
• 238000005119 centrifugation Methods 0.000 claims description 2
• 235000013339 cereals Nutrition 0.000 claims description 2
• 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 claims description 2
• 239000003610 charcoal Substances 0.000 claims description 2
• 238000001311 chemical methods and process Methods 0.000 claims description 2
• 239000007795 chemical reaction product Substances 0.000 claims description 2
• 239000003153 chemical reaction reagent Substances 0.000 claims description 2
• 238000002512 chemotherapy Methods 0.000 claims description 2
• 235000019693 cherries Nutrition 0.000 claims description 2
• 235000015120 cherry juice Nutrition 0.000 claims description 2
• 239000007910 chewable tablet Substances 0.000 claims description 2
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
• 229960001231 choline Drugs 0.000 claims description 2
• 239000010630 cinnamon oil Substances 0.000 claims description 2
• 238000010367 cloning Methods 0.000 claims description 2
• 239000010634 clove oil Substances 0.000 claims description 2
• 239000011248 coating agent Substances 0.000 claims description 2
• 238000000576 coating method Methods 0.000 claims description 2
• 229940110456 cocoa butter Drugs 0.000 claims description 2
• 235000019868 cocoa butter Nutrition 0.000 claims description 2
• 239000003240 coconut oil Substances 0.000 claims description 2
• 235000019864 coconut oil Nutrition 0.000 claims description 2
• 230000001113 coital effect Effects 0.000 claims description 2
• 238000005056 compaction Methods 0.000 claims description 2
• 239000002299 complementary DNA Substances 0.000 claims description 2
• 238000004590 computer program Methods 0.000 claims description 2
• 210000002808 connective tissue Anatomy 0.000 claims description 2
• 239000010636 coriander oil Substances 0.000 claims description 2
• 230000002596 correlated effect Effects 0.000 claims description 2
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
• 229960000258 corticotropin Drugs 0.000 claims description 2
• 150000003950 cyclic amides Chemical class 0.000 claims description 2
• 230000007423 decrease Effects 0.000 claims description 2
• 229940096516 dextrates Drugs 0.000 claims description 2
• 229960000673 dextrose monohydrate Drugs 0.000 claims description 2
• PWZFXELTLAQOKC-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide;tetrahydrate Chemical compound O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O PWZFXELTLAQOKC-UHFFFAOYSA-A 0.000 claims description 2
• 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 2
• UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 claims description 2
• 229940099364 dichlorofluoromethane Drugs 0.000 claims description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
• SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 claims description 2
• 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
• AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 2
• 235000019797 dipotassium phosphate Nutrition 0.000 claims description 2
• 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
• CVOQYKPWIVSMDC-UHFFFAOYSA-L dipotassium;butanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC([O-])=O CVOQYKPWIVSMDC-UHFFFAOYSA-L 0.000 claims description 2
• GOMCKELMLXHYHH-UHFFFAOYSA-L dipotassium;phthalate Chemical compound [K+].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O GOMCKELMLXHYHH-UHFFFAOYSA-L 0.000 claims description 2
• 238000007907 direct compression Methods 0.000 claims description 2
• MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 2
• 235000019800 disodium phosphate Nutrition 0.000 claims description 2
• 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
• HQWKKEIVHQXCPI-UHFFFAOYSA-L disodium;phthalate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C([O-])=O HQWKKEIVHQXCPI-UHFFFAOYSA-L 0.000 claims description 2
• LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 claims description 2
• 238000007580 dry-mixing Methods 0.000 claims description 2
• 238000001035 drying Methods 0.000 claims description 2
• 239000008157 edible vegetable oil Substances 0.000 claims description 2
• 239000007938 effervescent tablet Substances 0.000 claims description 2
• 239000001567 elettaria cardamomum seed Substances 0.000 claims description 2
• 230000002124 endocrine Effects 0.000 claims description 2
• 238000005516 engineering process Methods 0.000 claims description 2
• 210000003238 esophagus Anatomy 0.000 claims description 2
• 150000002148 esters Chemical class 0.000 claims description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
• 238000011156 evaluation Methods 0.000 claims description 2
• 239000013604 expression vector Substances 0.000 claims description 2
• 239000010685 fatty oil Substances 0.000 claims description 2
• 239000010643 fennel seed oil Substances 0.000 claims description 2
• 235000013305 food Nutrition 0.000 claims description 2
• 230000037406 food intake Effects 0.000 claims description 2
• 230000008014 freezing Effects 0.000 claims description 2
• 238000007710 freezing Methods 0.000 claims description 2
• 239000012737 fresh medium Substances 0.000 claims description 2
• 125000000524 functional group Chemical group 0.000 claims description 2
• 230000004927 fusion Effects 0.000 claims description 2
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims description 2
• 239000007903 gelatin capsule Substances 0.000 claims description 2
• 235000008397 ginger Nutrition 0.000 claims description 2
• 235000001727 glucose Nutrition 0.000 claims description 2
• 229960005150 glycerol Drugs 0.000 claims description 2
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
• 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
• 238000011194 good manufacturing practice Methods 0.000 claims description 2
• 239000005090 green fluorescent protein Substances 0.000 claims description 2
• 159000000011 group IA salts Chemical class 0.000 claims description 2
• 239000000665 guar gum Substances 0.000 claims description 2
• 235000010417 guar gum Nutrition 0.000 claims description 2
• 229960002154 guar gum Drugs 0.000 claims description 2
• 230000002008 hemorrhagic effect Effects 0.000 claims description 2
• 238000012735 histological processing Methods 0.000 claims description 2
• 235000012907 honey Nutrition 0.000 claims description 2
• 210000005260 human cell Anatomy 0.000 claims description 2
• 238000009396 hybridization Methods 0.000 claims description 2
• 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
• 230000002209 hydrophobic effect Effects 0.000 claims description 2
• 229910001701 hydrotalcite Inorganic materials 0.000 claims description 2
• 229960001545 hydrotalcite Drugs 0.000 claims description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 claims description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
• 238000009802 hysterectomy Methods 0.000 claims description 2
• 238000003018 immunoassay Methods 0.000 claims description 2
• 239000007943 implant Substances 0.000 claims description 2
• 230000001976 improved effect Effects 0.000 claims description 2
• 238000000338 in vitro Methods 0.000 claims description 2
• 238000001727 in vivo Methods 0.000 claims description 2
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 2
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims description 2
• 238000001802 infusion Methods 0.000 claims description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
• 229960000367 inositol Drugs 0.000 claims description 2
• 238000010255 intramuscular injection Methods 0.000 claims description 2
• 239000007927 intramuscular injection Substances 0.000 claims description 2
• 238000007914 intraventricular administration Methods 0.000 claims description 2
• 238000005342 ion exchange Methods 0.000 claims description 2
• 150000002500 ions Chemical class 0.000 claims description 2
• 229960001021 lactose monohydrate Drugs 0.000 claims description 2
• 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 2
• 235000010445 lecithin Nutrition 0.000 claims description 2
• 239000000787 lecithin Substances 0.000 claims description 2
• 229940067606 lecithin Drugs 0.000 claims description 2
• 239000010501 lemon oil Substances 0.000 claims description 2
• 229950001701 lilopristone Drugs 0.000 claims description 2
• 230000000670 limiting effect Effects 0.000 claims description 2
• 239000008263 liquid aerosol Substances 0.000 claims description 2
• 210000004185 liver Anatomy 0.000 claims description 2
• 238000011866 long-term treatment Methods 0.000 claims description 2
• 230000007774 longterm Effects 0.000 claims description 2
• 239000006210 lotion Substances 0.000 claims description 2
• 239000007937 lozenge Substances 0.000 claims description 2
• 210000004698 lymphocyte Anatomy 0.000 claims description 2
• UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
• 239000011654 magnesium acetate Substances 0.000 claims description 2
• 235000011285 magnesium acetate Nutrition 0.000 claims description 2
• 229940069446 magnesium acetate Drugs 0.000 claims description 2
• QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims description 2
• 239000002370 magnesium bicarbonate Substances 0.000 claims description 2
• 235000014824 magnesium bicarbonate Nutrition 0.000 claims description 2
• 229910000022 magnesium bicarbonate Inorganic materials 0.000 claims description 2
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
• 239000001095 magnesium carbonate Substances 0.000 claims description 2
• 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
• 229960001708 magnesium carbonate Drugs 0.000 claims description 2
• 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
• 239000004337 magnesium citrate Substances 0.000 claims description 2
• 229960005336 magnesium citrate Drugs 0.000 claims description 2
• 235000002538 magnesium citrate Nutrition 0.000 claims description 2
• 239000001755 magnesium gluconate Substances 0.000 claims description 2
• 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
• 229960003035 magnesium gluconate Drugs 0.000 claims description 2
• 229960000816 magnesium hydroxide Drugs 0.000 claims description 2
• OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
• 239000000626 magnesium lactate Substances 0.000 claims description 2
• 235000015229 magnesium lactate Nutrition 0.000 claims description 2
• 229960004658 magnesium lactate Drugs 0.000 claims description 2
• 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
• 239000000395 magnesium oxide Substances 0.000 claims description 2
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
• GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
• 239000004137 magnesium phosphate Substances 0.000 claims description 2
• 229960002261 magnesium phosphate Drugs 0.000 claims description 2
• 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
• 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
• 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
• 235000019792 magnesium silicate Nutrition 0.000 claims description 2
• 229960002366 magnesium silicate Drugs 0.000 claims description 2
• 229940095060 magnesium tartrate Drugs 0.000 claims description 2
• 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
• 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
• 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
• MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
• IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
• APLYTANMTDCWTA-UHFFFAOYSA-L magnesium;phthalate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1C([O-])=O APLYTANMTDCWTA-UHFFFAOYSA-L 0.000 claims description 2
• 230000036210 malignancy Effects 0.000 claims description 2
• 230000003211 malignant effect Effects 0.000 claims description 2
• 229940035034 maltodextrin Drugs 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 239000003550 marker Substances 0.000 claims description 2
• 239000000463 material Substances 0.000 claims description 2
• 230000007246 mechanism Effects 0.000 claims description 2
• 229940066974 medicated patch Drugs 0.000 claims description 2
• 239000012528 membrane Substances 0.000 claims description 2
• 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
• 230000002503 metabolic effect Effects 0.000 claims description 2
• 239000002207 metabolite Substances 0.000 claims description 2
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
• 229960002216 methylparaben Drugs 0.000 claims description 2
• 150000007522 mineralic acids Chemical class 0.000 claims description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 2
• 150000004682 monohydrates Chemical class 0.000 claims description 2
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
• 230000017074 necrotic cell death Effects 0.000 claims description 2
• 229940073555 nonoxynol-10 Drugs 0.000 claims description 2
• 229920004918 nonoxynol-9 Polymers 0.000 claims description 2
• 229940087419 nonoxynol-9 Drugs 0.000 claims description 2
• 235000019488 nut oil Nutrition 0.000 claims description 2
• 239000010466 nut oil Substances 0.000 claims description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
• 239000008601 oleoresin Substances 0.000 claims description 2
• 229950011093 onapristone Drugs 0.000 claims description 2
• 239000010502 orange oil Substances 0.000 claims description 2
• 150000007524 organic acids Chemical class 0.000 claims description 2
• 150000002914 oxasteroids Chemical class 0.000 claims description 2
• 239000012057 packaged powder Substances 0.000 claims description 2
• 238000004806 packaging method and process Methods 0.000 claims description 2
• RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 2
• 239000006072 paste Substances 0.000 claims description 2
• 235000010987 pectin Nutrition 0.000 claims description 2
• 239000001814 pectin Substances 0.000 claims description 2
• 229920001277 pectin Polymers 0.000 claims description 2
• 239000008188 pellet Substances 0.000 claims description 2
• 235000019477 peppermint oil Nutrition 0.000 claims description 2
• 230000002093 peripheral effect Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
• 230000000144 pharmacologic effect Effects 0.000 claims description 2
• 238000009520 phase I clinical trial Methods 0.000 claims description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
• 229940067107 phenylethyl alcohol Drugs 0.000 claims description 2
• 239000010452 phosphate Substances 0.000 claims description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
• 229910052698 phosphorus Inorganic materials 0.000 claims description 2
• 239000011574 phosphorus Substances 0.000 claims description 2
• 125000005498 phthalate group Chemical class 0.000 claims description 2
• 239000006187 pill Substances 0.000 claims description 2
• 230000003169 placental effect Effects 0.000 claims description 2
• 239000013612 plasmid Substances 0.000 claims description 2
• 229920001983 poloxamer Polymers 0.000 claims description 2
• 229920000193 polymethacrylate Polymers 0.000 claims description 2
• 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 claims description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
• 229920001451 polypropylene glycol Polymers 0.000 claims description 2
• 229920001282 polysaccharide Polymers 0.000 claims description 2
• 239000005017 polysaccharide Substances 0.000 claims description 2
• 150000004804 polysaccharides Chemical class 0.000 claims description 2
• 229920000136 polysorbate Polymers 0.000 claims description 2
• 229940068977 polysorbate 20 Drugs 0.000 claims description 2
• 229940068968 polysorbate 80 Drugs 0.000 claims description 2
• 229920000053 polysorbate 80 Polymers 0.000 claims description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
• 239000013641 positive control Substances 0.000 claims description 2
• 239000011591 potassium Substances 0.000 claims description 2
• 229960003975 potassium Drugs 0.000 claims description 2
• 229910052700 potassium Inorganic materials 0.000 claims description 2
• AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims description 2
• 235000011056 potassium acetate Nutrition 0.000 claims description 2
• 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
• 239000011736 potassium bicarbonate Substances 0.000 claims description 2
• 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
• 235000011181 potassium carbonates Nutrition 0.000 claims description 2
• 239000001508 potassium citrate Substances 0.000 claims description 2
• 229960002635 potassium citrate Drugs 0.000 claims description 2
• QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
• 235000011082 potassium citrates Nutrition 0.000 claims description 2
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
• RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 claims description 2
• 229940043349 potassium metabisulfite Drugs 0.000 claims description 2
• 235000010263 potassium metabisulphite Nutrition 0.000 claims description 2
• 229940099402 potassium metaphosphate Drugs 0.000 claims description 2
• 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
• 235000019828 potassium polyphosphate Nutrition 0.000 claims description 2
• 239000001472 potassium tartrate Substances 0.000 claims description 2
• 229940111695 potassium tartrate Drugs 0.000 claims description 2
• 235000011005 potassium tartrates Nutrition 0.000 claims description 2
• 230000003389 potentiating effect Effects 0.000 claims description 2
• 230000002335 preservative effect Effects 0.000 claims description 2
• 238000011112 process operation Methods 0.000 claims description 2
• 239000000047 product Substances 0.000 claims description 2
• 150000003146 progesterones Chemical class 0.000 claims description 2
• 230000005522 programmed cell death Effects 0.000 claims description 2
• 239000003380 propellant Substances 0.000 claims description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
• 229960003415 propylparaben Drugs 0.000 claims description 2
• 150000004892 pyridazines Chemical class 0.000 claims description 2
• 235000013995 raspberry juice Nutrition 0.000 claims description 2
• 235000020440 raspberry syrup Nutrition 0.000 claims description 2
• 239000000376 reactant Substances 0.000 claims description 2
• 238000001525 receptor binding assay Methods 0.000 claims description 2
• 230000006798 recombination Effects 0.000 claims description 2
• 238000005215 recombination Methods 0.000 claims description 2
• 239000006215 rectal suppository Substances 0.000 claims description 2
• 108010054624 red fluorescent protein Proteins 0.000 claims description 2
• 239000011347 resin Substances 0.000 claims description 2
• 229920005989 resin Polymers 0.000 claims description 2
• 230000002441 reversible effect Effects 0.000 claims description 2
• 239000010666 rose oil Substances 0.000 claims description 2
• 235000019719 rose oil Nutrition 0.000 claims description 2
• 239000008132 rose water Substances 0.000 claims description 2
• 239000010668 rosemary oil Substances 0.000 claims description 2
• 229940058206 rosemary oil Drugs 0.000 claims description 2
• 229940081974 saccharin Drugs 0.000 claims description 2
• 235000019204 saccharin Nutrition 0.000 claims description 2
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
• 229940043243 saccharin calcium Drugs 0.000 claims description 2
• 229940085605 saccharin sodium Drugs 0.000 claims description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
• 238000007873 sieving Methods 0.000 claims description 2
• 229910052710 silicon Inorganic materials 0.000 claims description 2
• 239000010703 silicon Substances 0.000 claims description 2
• 229940083037 simethicone Drugs 0.000 claims description 2
• 238000004513 sizing Methods 0.000 claims description 2
• HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
• 235000010234 sodium benzoate Nutrition 0.000 claims description 2
• 239000004299 sodium benzoate Substances 0.000 claims description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
• 235000017550 sodium carbonate Nutrition 0.000 claims description 2
• 239000011780 sodium chloride Substances 0.000 claims description 2
• 239000001509 sodium citrate Substances 0.000 claims description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
• 235000011083 sodium citrates Nutrition 0.000 claims description 2
• 235000019294 sodium fumarate Nutrition 0.000 claims description 2
• 229940005573 sodium fumarate Drugs 0.000 claims description 2
• 235000012207 sodium gluconate Nutrition 0.000 claims description 2
• 239000000176 sodium gluconate Substances 0.000 claims description 2
• 229940005574 sodium gluconate Drugs 0.000 claims description 2
• 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
• 239000001540 sodium lactate Substances 0.000 claims description 2
• 235000011088 sodium lactate Nutrition 0.000 claims description 2
• 229940005581 sodium lactate Drugs 0.000 claims description 2
• 239000011684 sodium molybdate Substances 0.000 claims description 2
• 235000015393 sodium molybdate Nutrition 0.000 claims description 2
• TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 2
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
• 235000019830 sodium polyphosphate Nutrition 0.000 claims description 2
• 229940048086 sodium pyrophosphate Drugs 0.000 claims description 2
• 235000018341 sodium sesquicarbonate Nutrition 0.000 claims description 2
• 229910000031 sodium sesquicarbonate Inorganic materials 0.000 claims description 2
• 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
• 239000008109 sodium starch glycolate Substances 0.000 claims description 2
• 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
• 229940074404 sodium succinate Drugs 0.000 claims description 2
• 239000001433 sodium tartrate Substances 0.000 claims description 2
• 229960002167 sodium tartrate Drugs 0.000 claims description 2
• 235000011004 sodium tartrates Nutrition 0.000 claims description 2
• 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
• 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
• QAPBSWSVUFGPJE-CVBJKYQLSA-M sodium;(z)-octadec-9-enoate;(z)-octadec-9-enoic acid Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O QAPBSWSVUFGPJE-CVBJKYQLSA-M 0.000 claims description 2
• 230000007928 solubilization Effects 0.000 claims description 2
• 238000005063 solubilization Methods 0.000 claims description 2
• 235000010199 sorbic acid Nutrition 0.000 claims description 2
• 239000004334 sorbic acid Substances 0.000 claims description 2
• 229940075582 sorbic acid Drugs 0.000 claims description 2
• 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
• 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 2
• 239000001570 sorbitan monopalmitate Substances 0.000 claims description 2
• 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 2
• 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
• 239000001587 sorbitan monostearate Substances 0.000 claims description 2
• 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
• 238000013223 sprague-dawley female rat Methods 0.000 claims description 2
• 239000008117 stearic acid Substances 0.000 claims description 2
• 230000001954 sterilising effect Effects 0.000 claims description 2
• 238000004659 sterilization and disinfection Methods 0.000 claims description 2
• 102000005969 steroid hormone receptors Human genes 0.000 claims description 2
• 230000004936 stimulating effect Effects 0.000 claims description 2
• 150000003890 succinate salts Chemical class 0.000 claims description 2
• 235000019408 sucralose Nutrition 0.000 claims description 2
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
• 239000006228 supernatant Substances 0.000 claims description 2
• 230000000153 supplemental effect Effects 0.000 claims description 2
• 239000002511 suppository base Substances 0.000 claims description 2
• 230000008961 swelling Effects 0.000 claims description 2
• 238000003786 synthesis reaction Methods 0.000 claims description 2
• 239000007916 tablet composition Substances 0.000 claims description 2
• 150000003892 tartrate salts Chemical class 0.000 claims description 2
• 239000006068 taste-masking agent Substances 0.000 claims description 2
• FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 2
• OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 claims description 2
• RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 claims description 2
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 2
• 230000004797 therapeutic response Effects 0.000 claims description 2
• 239000002562 thickening agent Substances 0.000 claims description 2
• 239000010678 thyme oil Substances 0.000 claims description 2
• 210000001541 thymus gland Anatomy 0.000 claims description 2
• 238000011200 topical administration Methods 0.000 claims description 2
• 230000000699 topical effect Effects 0.000 claims description 2
• 231100000331 toxic Toxicity 0.000 claims description 2
• 230000002588 toxic effect Effects 0.000 claims description 2
• 231100000419 toxicity Toxicity 0.000 claims description 2
• 230000001988 toxicity Effects 0.000 claims description 2
• 235000010487 tragacanth Nutrition 0.000 claims description 2
• 239000000196 tragacanth Substances 0.000 claims description 2
• 229940116362 tragacanth Drugs 0.000 claims description 2
• 238000001890 transfection Methods 0.000 claims description 2
• 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
• 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
• VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 claims description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 2
• 229940029284 trichlorofluoromethane Drugs 0.000 claims description 2
• 229940117013 triethanolamine oleate Drugs 0.000 claims description 2
• PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
• NFMWFGXCDDYTEG-UHFFFAOYSA-N trimagnesium;diborate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]B([O-])[O-].[O-]B([O-])[O-] NFMWFGXCDDYTEG-UHFFFAOYSA-N 0.000 claims description 2
• WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 claims description 2
• 235000019798 tripotassium phosphate Nutrition 0.000 claims description 2
• 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 2
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
• 235000019801 trisodium phosphate Nutrition 0.000 claims description 2
• 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 2
• WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 claims description 2
• 229960000281 trometamol Drugs 0.000 claims description 2
• 230000005748 tumor development Effects 0.000 claims description 2
• 230000002100 tumorsuppressive effect Effects 0.000 claims description 2
• MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 2
• 229960004224 tyloxapol Drugs 0.000 claims description 2
• 229920001664 tyloxapol Polymers 0.000 claims description 2
• 239000013598 vector Substances 0.000 claims description 2
• 229920002554 vinyl polymer Polymers 0.000 claims description 2
• 239000004552 water soluble powder Substances 0.000 claims description 2
• 239000001993 wax Substances 0.000 claims description 2
• 238000005303 weighing Methods 0.000 claims description 2
• 239000013585 weight reducing agent Substances 0.000 claims description 2
• 238000009736 wetting Methods 0.000 claims description 2
• 229920001285 xanthan gum Polymers 0.000 claims description 2
• 239000000811 xylitol Substances 0.000 claims description 2
• 235000010447 xylitol Nutrition 0.000 claims description 2
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
• 229960002675 xylitol Drugs 0.000 claims description 2
• 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 2
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
• 229910002012 Aerosil® Inorganic materials 0.000 claims 3
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 3
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 2
• DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims 1
• KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 claims 1
• HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 claims 1
• 229960002903 benzyl benzoate Drugs 0.000 claims 1
• 229920002114 octoxynol-9 Polymers 0.000 claims 1
• 229940098514 octoxynol-9 Drugs 0.000 claims 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
• 229960004622 raloxifene Drugs 0.000 claims 1
• 239000003981 vehicle Substances 0.000 claims 1
• 239000002379 progesterone receptor modulator Substances 0.000 abstract description 12
• 230000002265 prevention Effects 0.000 abstract 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
• 201000010099 disease Diseases 0.000 description 14
• 208000035475 disorder Diseases 0.000 description 9
• 230000006870 function Effects 0.000 description 7
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 6
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
• WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 241000282553 Macaca Species 0.000 description 2
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
• 102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 108010080146 androgen receptors Proteins 0.000 description 2
• 239000000051 antiandrogen Substances 0.000 description 2
• 208000037824 growth disorder Diseases 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 238000001794 hormone therapy Methods 0.000 description 2
• 229960004400 levonorgestrel Drugs 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 230000009758 senescence Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• ALSXNTIVNJBNQE-ZWONNITHSA-N (8r,9r,10s,13r,14s,17s)-17-ethyl-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical class C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 ALSXNTIVNJBNQE-ZWONNITHSA-N 0.000 description 1
• CXIISRLRZRAKST-UHFFFAOYSA-N 29‐(4‐nonylphenoxy)‐3,6,9,12,15,18,21,24,27‐ nonaoxanonacosan‐1‐ol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 CXIISRLRZRAKST-UHFFFAOYSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 206010012559 Developmental delay Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 206010027940 Mood altered Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 229950003620 asoprisnil Drugs 0.000 description 1
• WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 102000027411 intracellular receptors Human genes 0.000 description 1
• 108091008582 intracellular receptors Proteins 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 201000003102 mental depression Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000007510 mood change Effects 0.000 description 1
• 229940053934 norethindrone Drugs 0.000 description 1
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
• 238000005549 size reduction Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 230000005186 women's health Effects 0.000 description 1